Thermo Fisher brings COVID-19 test for transplant community

11 August 2020 | News

The assay will be submitted for Emergency Use Authorization (EUA)

Image credit-

Image credit-

Thermo Fisher Scientific continues to expand its response to the COVID-19 pandemic, developing a new serological assay targeted towards transplant candidates and recipients that can detect antibodies directed against COVID-19 (SARS-CoV-2).

The assay will be provided under the company's One Lambda brand representing leading in vitro diagnostic products for the transplant community. 

This novel antibody detection panel is part of Thermo Fisher's continued efforts to support transplant patients during the pandemic.

In collaboration with histocompatibility, infectious disease and nephrology laboratories at Emory UniversityStanford UniversityUniversity of Cincinnati and the University Health Network in TorontoThermo Fisher's transplant diagnostic business has developed the LABScreen COVID Plus Assay.

The assay leverages the Luminex xMAP technology to detect multiple distinct antibodies and fragments, making it more specific than current assays and able to reduce false positives caused by infections with common coronavirus. In combination with HLA antibody detection, the LABScreen COVID Plus reagents can help provide a more complete picture of a patient's antibody profile.

The LABScreen COVID Plus Assay will be available for research use only by August 2020.  Additionally, the assay will be submitted for Emergency Use Authorization (EUA).


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account